Pharmacomicrobiomics in precision pharmacotherapy: bidirectional microbial-drug interactions as a key determinant of therapeutic response
Yazarlar (3)
Prof. Dr. Serap YALÇIN AZARKAN Kırşehir Ahi Evran Üniversitesi, Türkiye
Habibe Sema Arslan Unal
Dr. Öğr. Üyesi Sevinç AKÇAY Kırşehir Ahi Evran Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | DRUG METABOLISM REVIEWS (Q1) | ||
| Dergi ISSN | 0360-2532 Dergi Bilgileri (2026) | ||
| Makale Dili | İngilizce | Basım Tarihi | 05-2026 |
| Cilt / Sayı / Sayfa | 0 / 0 / 1–21 | DOI | 10.1080/03602532.2026.2671428 |
| Makale Linki | https://www.tandfonline.com/doi/abs/10.1080/03602532.2026.2671428 | ||
| UAK Araştırma Alanları |
|
||
| Özet |
| Interindividual variability in drug efficacy and toxicity remains a major challenge in clinical pharmacotherapy. Although pharmacogenomics has substantially advanced personalized medicine, host genetic variation alone cannot fully explain differences in drug disposition, response, and adverse effects. Increasing evidence identifies the human gut microbiota as an additional, functionally relevant metabolic layer that complements host drug-metabolizing enzymes, giving rise to the field of pharmacomicrobiomics. This discipline examines bidirectional interactions between drugs and microbial communities that influence absorption, metabolism, enterohepatic circulation, and pharmacodynamic outcomes. The gut microbiota can directly biotransform or sequester drugs through diverse enzymatic reactions, including deconjugation, reduction, and decarboxylation, thereby modifying systemic drug exposure and toxicity. In … |
| Anahtar Kelimeler |
| Pharmacomicrobiomics | drug metabolism | gut microbiota | xenobiotic biotransformation | pharmacokinetics | precision pharmacotherapy |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 1 |